729 results on '"Leoni, Pietro"'
Search Results
102. Use of Lenalidomide in DEL(5q) MDS. a National AIFA (Agenzia Italiana del Farmaco) Registry Study
103. Bone marrow adipocytes support hematopoietic stem cell survival.
104. Human germinal center–associated lymphoma (HGAL) expression in B-cell follicles in hyperplastic lymph nodes and malignant follicular lymphomas
105. Abstract 5491: Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience
106. Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis
107. Biosafety evidence for human dedifferentiated adipocytes
108. Plasticity of human dedifferentiated adipocytes toward endothelial cells
109. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
110. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
111. Primary B-cell lymphoblastic lymphoma of the testis
112. Preventive Effects of Cardotoxicities By Liposomal Anthracyclines non Pegilated in 95 Perspective Patients Affected By Lymphoma and Monitored By Biomarkers and Ecocardiography
113. Azacitidine Treatment in High Risk Myelodysplastic Patients in Complete Haematological Remission Reverts Mesenchymal Stem Cells to a Normal Phenotype
114. Azacitidine As Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia Significantly Prolongs Disease-Free Survival: Interim Results from a Prospective, Randomized, Open-Label, Phase III Multicenter Trial
115. Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study
116. Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial
117. Fatal Necrotizing Angiotropic Epstein–Barr Virus-negative Large B-cell Lymphoma
118. DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype.
119. Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408
120. Glial-Like Differentiation Potential of Human Mature Adipocytes
121. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
122. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2
123. Imatinib for refractory chronic graft-versus-host disease with fibrotic features
124. Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy
125. Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party
126. Nilotinib For Steroid-Refractory Chronic Graft Versus Host Disease (SR-cGVHD): Preliminary Results Of a Phase I-II GITMO Study (Gruppo Italiano Trapianto di Midollo Osseo)
127. Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)
128. A Randomized Open-Label Study To Evaluate The Efficacy Of Azacitidine For Post-Remission Therapy Of Acute Myeloid Leukemia In Elderly Patients (QOLESS AZA-AMLE)
129. Geriatric Assessment Driven Treatment In 149 AML Elderly Patients
130. Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma
131. Molecular and functional characterization of human bone marrow adipocytes
132. Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.
133. Reversal of poor graft function with iron-chelating therapy after allogeneic transplantation for severe aplastic anemia.
134. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine
135. Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)
136. Efficacy and Feasibility of High-Dose Cytarabine Plus Idarubicin and Amifostine As Induction Schedule: A Prospective Observational Study of 100 AML Elderly Fit Patients
137. Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry
138. Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)
139. Risk of Thromboembolic Events in ET and Early/Prefibrotic PMF: The Relevance of an Accurate Histological Diagnosis
140. Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.
141. Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA
142. Human Dedifferentiated Adipocytes Show Similar Properties to Bone Marrow‐Derived Mesenchymal Stem Cells
143. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
144. TRPV2 Expression and Its Role in Proliferation of Human Multiple Myeloma Cell Lines
145. Evaluation of Therapy in Symptomatic Patients with Lymphoproliferative Disorders of Large Granular Lymphocytes in Italy
146. Retrospective Analysis of Infections In An Unselected Cohort of Patients with Multiple Myeloma Treated with Lenalidomide Combinations Therapies
147. Assessment of Frailty Measures and Their Effect on Survival in a Population of Patients Registered At Marche Region Multiple Myeloma (MM) Registry
148. Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas
149. Human Mesenchymal Stem Cells from Chorionic Villi and Amniotic Fluid are not Susceptible to Transformation after Extensive in Vitro Expansion
150. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.